The downside of downsizing: playing it safe

"Gone are the people who acquired the experience to know what doesn't work... Those with sufficient boldness to try something outside the conventional axioms now spend their mornings expanding their LinkedIn contacts," laments Daniel Hoffman, president at Pharmaceutical Business Research Associates, in Pharmalot. The result? Politically savvy, play-it-safe employees, those least likely to drive the changes needed to get pharma growing again. Op-Ed

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.